The completion of the human genome gave hope for a new age of medical understanding, but 4-5 years later costs of drug development are still rising and the success rate has not improved. Drugs that have already hit the market are found to have major side effects not perceived in the past and are often given to patients without discrimination on their likeliness to respond.
Large scale methodologies that thrive in recent years, allowed the industry and academia to gather more information on RNAs and proteins. However, the understanding of the molecular and cellular processes is still lacking, not to mention the connection to the clinical outcome. In order to fully use this data, a comprehensive integration and modelling effort is needed. A systematic rational hypothesis-driven research approach connecting all those levels of information is a much needed computational tool. This is the main goal of SIMAP project.
The ultimate goal of SIMAP is to develop a comprehensive simulation biochemical model of EGFRMAP kinase pathway in connection to cancer clinical information. SIMAP will:
- Incorporate low-level biochemical modelling of individual molecules;
- Simulate the behaviour of the pathway;
- Add genomic and proteomic data;
- Incorporate individual patients responses; and
- Analyze sub population of responses in the context of the biochemical behaviour and genotype data
For further information, please visit:
http://www.simap-project.org
Project co-ordinator:
Compugen Ltd.
Partners:
- Aureus Pharma, (FR)
- Compugen Ltd., (IL)
- Consejo Superior de Investigaciones Científicas, (ES)
- Halevi Dweck & Co.Arttic Israel Company Ltd., (IL)
- Fundacio Institut De Recerca De L'Hospital Universitari Vall D'Hebron, (ES)
- Fondazione IRCCS Istituto Nazionale Dei Tumori, (IT)
- The Max-Planck Institute for Infection Biology, (DE)
- The University of Glasgow, (UK)
- The Weizmann Institute of Science, (IL)
Timetable: from 01/06 to 12/08
Total cost: 4.464.201
EC funding: 3.126.662
Instrument: STREP
Project Identifier: IST-2004-027265